Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

RNA Splicing

RNA Splicing

Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...

RNA Splicing

RNA Splicing

Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...

Nonsense-mediated mRNA Decay

Nonsense-mediated mRNA Decay

The Upf proteins that carry out nonsense-mediated decay (NMD) are found in all eukaryotic organisms, including humans. Each protein has an individual role, but they need to work in collaboration. Upf1 is an ATP-dependent RNA helicase that unwinds the RNA helix. Because Upf1 can unwind any RNA, Upf2 and Upf3 are required to help Upf1 discriminate between nonsense and normal mRNAs.
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...

Alternative RNA Splicing

Alternative RNA Splicing

Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...

Chromatin Structure Regulates pre-mRNA Processing

Chromatin Structure Regulates pre-mRNA Processing

In eukaryotic cells, nascent mRNA transcripts need to undergo many post-transcriptional modifications to reach the cell cytoplasm and translate into functional proteins. For a long time, transcription and pre-mRNA processing were considered two independent events that occur sequentially in the cell. However, it has now been well established that transcription and pre-mRNA processing are two simultaneous processes that are precisely regulated inside the cell.
The chromatin structure, especially...

Nucleotide Excision Repair

Nucleotide Excision Repair

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Loss of SARM1 Improves Phenotypes in a Mouse Model of Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay.

Neurology. Genetics·2026

Same author

A human Staufen1 BAC transgenic mouse exhibits abnormal autophagy and neurodegeneration across the central nervous system.

Cell death & disease·2026

Same author

Viral vector-mediated SLC9A6 gene replacement reduces cerebellar motor and molecular abnormalities in the shaker rat model of Christianson syndrome.

Human molecular genetics·2026

Same author

Targeting STAU1 prevents p53 apoptotic signaling in neurodegeneration.

Cell death & disease·2025

Same author

A human Staufen1 BAC transgenic mouse exhibits abnormal autophagy and neurodegeneration across the central nervous system.

Research square·2025

Same author

Targeting CTP synthetase 1 to restore interferon induction and impede nucleotide synthesis in SARS-CoV-2 infection.

mBio·2025

Search research articles

Related Experiment Video

Updated: May 16, 2026

Using the E1A Minigene Tool to Study mRNA Splicing Changes

Using the E1A Minigene Tool to Study mRNA Splicing Changes

Published on: April 22, 2021

RNA splicing is responsive to MBNL1 dose.

Sonali P Jog¹, Sharan Paul, Warunee Dansithong

¹Department of Biochemistry and Molecular Biology, Institute for Genetic Medicine, University of Southern California, Los Angeles, California, USA.

|November 21, 2012

Summary

Myotonic dystrophy type 1 (DM1) symptoms vary due to MBNL1 protein levels. Lower MBNL1 levels cause more severe RNA splicing defects, explaining DM1 phenotype variability.

More Related Videos

A Reporter Based Cellular Assay for Monitoring Splicing Efficiency

A Reporter Based Cellular Assay for Monitoring Splicing Efficiency

Published on: September 15, 2021

Related Experiment Videos

Last Updated: May 16, 2026

Using the E1A Minigene Tool to Study mRNA Splicing Changes

Using the E1A Minigene Tool to Study mRNA Splicing Changes

Published on: April 22, 2021

A Reporter Based Cellular Assay for Monitoring Splicing Efficiency

A Reporter Based Cellular Assay for Monitoring Splicing Efficiency

Published on: September 15, 2021

Area of Science:

Molecular Biology
Genetics
RNA Biology

Background:

Myotonic dystrophy type 1 (DM1) is a multisystem disorder caused by expanded CTG repeats in the DMPK gene.
Expanded CUG repeat RNAs sequester the RNA splice regulator MBNL1, leading to splice defects and DM1 pathology.
While CTG repeat length correlates with DM1 severity, significant phenotype variability exists among patients.

Purpose of the Study:

To investigate the relationship between MBNL1 levels and the number/severity of RNA splice defects in DM1.
To explore how MBNL1 depletion contributes to the observed variability in DM1 patient phenotypes.

Main Methods:

Analysis of MBNL1 levels in relation to splice defect repertoire and severity.
Assessment of the impact of gradual MBNL1 decrease on RNA splicing.
Correlation of MBNL1 dose variations with DM1 phenotype variability.

Main Results:

A gradual decrease in MBNL1 levels expands the range of splice defects and increases their severity.
MBNL1 loss has a graded effect on splice defects, not an all-or-none outcome.
Small variations in free MBNL1 levels, influenced by CUG tract size and hairpin formation, significantly alter splice abnormalities.

Conclusions:

MBNL1 depletion's impact on RNA splicing is dose-dependent, contributing to DM1 phenotype variability.
Modest changes in MBNL1 levels, beyond a critical threshold, significantly affect splice defect severity and number.
Understanding MBNL1's graded effect is crucial for explaining DM1 patient variability and potential therapeutic strategies.